Patents Assigned to F. Hoffmann-La Roche AG
-
Patent number: 8987260Abstract: Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate.Type: GrantFiled: February 6, 2014Date of Patent: March 24, 2015Assignee: F. Hoffmann-La Roche AGInventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Patent number: 8987280Abstract: Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: January 29, 2009Date of Patent: March 24, 2015Assignees: Genentech, Inc., F. Hoffmann-La Roche AGInventors: Jennafer Dotson, Tim Heffron, Alan Olivero, Daniel P. Sutherlin, Shumei Wang, Bing-Yan Zhu, Irina Chuckowree, Adrian Folkes, Nan Chi Wan
-
Patent number: 8952039Abstract: The present invention relates to a compound having the general formula (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.Type: GrantFiled: January 7, 2014Date of Patent: February 10, 2015Assignees: European Molecular Biology Laboratory, F. Hoffmann-La Roche AG, Savira pharmaceuticals GmbHInventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Helmut Buschmann, Stephen Cusack, Mark Smith, Sung-Sau So, Ronald Charles Hawley
-
Patent number: 8946217Abstract: Fused pyrimidines of formula (I): wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: GrantFiled: June 17, 2014Date of Patent: February 3, 2015Assignee: F. Hoffmann-La Roche AGInventors: Stephen J. Shuttleworth, Adrian J. Folkes, Irina S. Chuckowree, Nan Chi Wan, Timothy C. Hancox, Stewart J. Baker, Sukhjit Sohal, Mohammed A. Latif
-
Publication number: 20150031690Abstract: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: ApplicationFiled: January 23, 2013Publication date: January 29, 2015Applicants: F. Hoffmann-La Roche AG, Siena Biotech S.P.AInventors: Hans Hilpert, Roland Humm, Thomas Woltering
-
Publication number: 20150017078Abstract: Sample handling system for handling samples contained in tubes (4), each tube (4) having a hollow body, a closed bottom and an open top for accessing the sample contained in the tube (4). The system comprises a micro-plate (1) comprising at least one grid insert (2) having a plurality of compartments. Each compartment comprises one or more side walls laterally confining a through-hole for receiving a said tube (4). The through-hole has a top opening and a bottom opening and extends between the top opening and the bottom opening. A frame (3) to which the at least one separate grid insert (2) is to be attached to form the micro-plate (1). The frame (3) laterally confines a through-opening which is dimensioned to allow for accessing each compartment (21) of the attached at least one grid insert (2) from above and from below. This allows for moving such tube (4) into and out of each compartment (21) through each of the top opening (202) and the bottom opening (203) of the through-hole (201).Type: ApplicationFiled: February 1, 2013Publication date: January 15, 2015Applicant: F. HOFFMANN-LA ROCHE AGInventors: Christof Fattinger, Tom Kissling, Thomas Zumstein
-
Patent number: 8921388Abstract: The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.Type: GrantFiled: August 5, 2013Date of Patent: December 30, 2014Assignees: European Molecular Biology Laboratory, F. Hoffmann-La Roche AG, Savira pharmaceuticals GmbHInventors: Helmut Buschmann, Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Stephen Cusack, Mark Smith, Sung-Sau So
-
Patent number: 8877510Abstract: A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyzer.Type: GrantFiled: November 22, 2013Date of Patent: November 4, 2014Assignee: F. Hoffmann-La Roche AGInventors: Andreas Calatzis, Ben Krüger, Marc Wittwer
-
Publication number: 20140315856Abstract: A method for treating cancer that includes administering a pharmaceutically effective amount of a composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents a 5- to 10-membered heteroaryl group, or a C6-10 aryl group; R1 and R2 independently represent H, OH, X, CN, NO2, a C1-4 haloalkyl group, a C1-6 alkyl group, or the like <R1 and R2 together form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group>; R3 represents H, a C1-5 alkyl group, a C6-10 aryl group, a C1-5 alkyl group, or a C1-4 haloalkyl group; and R4 represents H, X, a C1-3 alkyl group, a C1-4 haloalkyl group, OH, CN, NO2, or the like.Type: ApplicationFiled: June 6, 2014Publication date: October 23, 2014Applicants: F. HOFFMANN-LA ROCHE AG, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Naoki Taka, Masayuki Ohmori, Kyoko Takami, Masayuki Matsushita, Tadakatsu Hayase, Ikumi Hyodo, Masami Kochi, Hiroki Nishii, Hirosato Ebiike, Yoshito Nakanishi, Toshiyuki Mio, Lisha Wang, Weili Zhao
-
Publication number: 20140314748Abstract: The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations.Type: ApplicationFiled: March 13, 2014Publication date: October 23, 2014Applicants: F. Hoffmann-La Roche AG, Genentech, Inc.Inventors: Yatin GOKARN, Isidro E. ZARRAGA, Jonathan ZARZAR, Thomas PATAPOFF, Christine WURTH
-
Patent number: 8846762Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: January 10, 2013Date of Patent: September 30, 2014Assignees: Genentech, Inc., F. Hoffmann-La Roche AGInventors: Steven Do, Richard Goldsmith, Tim Heffron, Aleksandr Kolesnikov, Steven Staben, Alan G. Olivero, Michael Siu, Daniel P. Sutherlin, Bing-Yan Zhu, Paul Goldsmith, Tracy Bayliss, Adrian Folkes, Neil Pegg
-
Patent number: 8829199Abstract: A compound represented by formula (I) or a pharmacologically acceptable salt thereof, which can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues. (In the formula, A represents a 5- to 10-membered heteroaryl group, or a C6-10 aryl group; R1 and R2 independently represent H, OH, X, CN, NO2, a C1-4 haloalkyl group, a C1-6 alkyl group, or the like <R1 and R2 together form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group>; R3 represents H, a C1-5 alkyl group, a C6-10 aryl group, a C1-5 alkyl group, or a C1-4 haloalkyl group; and R4 represents H, X, a C1-3 alkyl group, a C1-4 haloalkyl group, OH, CN, NO2, or the like.Type: GrantFiled: August 5, 2010Date of Patent: September 9, 2014Assignees: Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche AGInventors: Naoki Taka, Masayuki Ohmori, Kyoko Takami, Masayuki Matsushita, Tadakatsu Hayase, Ikumi Hyodo, Masami Kochi, Hiroki Nishii, Hirosato Ebiike, Yoshito Nakanishi, Toshiyuki Mio, Lisha Wang, Weili Zhao
-
Patent number: 8802670Abstract: Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: April 24, 2007Date of Patent: August 12, 2014Assignees: F. Hoffmann-La Roche AG, Genentech, Inc.Inventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Bing-Yan Zhu
-
Publication number: 20140221367Abstract: Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate.Type: ApplicationFiled: February 6, 2014Publication date: August 7, 2014Applicant: F. HOFFMANN-LA ROCHE AGInventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Patent number: 8771685Abstract: The present invention concerns antibodies to Bv8 and the uses of same.Type: GrantFiled: December 22, 2010Date of Patent: July 8, 2014Assignee: F. Hoffmann-La Roche AGInventors: Xiumin Wu, Yan Wu, Lanlan Yu, Napoleone Ferrara, Wei-Ching Liang, Yu-Ju G. Meng, Janet Tien
-
Patent number: 8754077Abstract: 8-Fluorophthalazin-1(2h)-one compounds of Formula I where one or two of X1, X2, and X3 are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: January 13, 2014Date of Patent: June 17, 2014Assignee: F. Hoffmann-La Roche AGInventors: James J. Crawford, Daniel F. Ortwine, BinQing Wei, Wendy B. Young
-
Publication number: 20140154810Abstract: A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyser.Type: ApplicationFiled: November 22, 2013Publication date: June 5, 2014Applicant: F. HOFFMANN-LA ROCHE AGInventors: Andreas Calatzis, Ben Krüger, Marc Wittwer
-
Patent number: 8697708Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.Type: GrantFiled: September 14, 2011Date of Patent: April 15, 2014Assignee: F. Hoffmann-La Roche AGInventors: Toby Jonathan Blench, Charles Ellwood, Simon Charles Goodacre, Yingjie Lai, Jun Liang, Calum Macleod, Steven R. Magnuson, Vickie H. Tsui, Karen Williams, Birong Zhang
-
Patent number: 8685968Abstract: Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate.Type: GrantFiled: November 5, 2012Date of Patent: April 1, 2014Assignee: F. Hoffmann-La Roche AGInventors: Irina Chuckowree, Adrian Folkes, Tim Hancox, Stephen Shuttleworth
-
Patent number: 8669361Abstract: Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: March 15, 2013Date of Patent: March 11, 2014Assignee: F. Hoffmann-La Roche AGInventor: Xiaojing Wang